highperformr logo

Carisma Therapeutics's Overview

Total employees69
HeadquartersPhiladelphia
Founded2016

Carisma Therapeutics, Inc. is a clinical-stage biopharmaceutical company at the forefront of immuno-oncology, dedicated to revolutionizing cancer treatment through the development of engineered macrophage-based therapeutics. Their proprietary platform focuses on harnessing the power of macrophages, a type of white blood cell, by engineering them with chimeric antigen receptors (CARs) to target and destroy cancer cells. This innovative CAR-Macrophage (CAR-M) approach offers a differentiated mechanism of action compared to other cell therapies, potentially overcoming limitations of current treatments and addressing a broader range of solid tumors. Carisma is advancing a pipeline of programs, with its lead candidate, CT-0508, an anti-HER2 CAR-M, in clinical trials for patients with HER2-overexpressing solid tumors. The company is committed to scientific excellence and translating groundbreaking research into life-changing medicines for patients with unmet medical needs.

Where is Carisma Therapeutics's Headquarters?

HQ Function

Serves as the central hub for all research and development, clinical operations, and corporate functions. This includes laboratory research, process development, clinical trial management, and administrative activities.

Notable Features:

Located within the uCity Square innovation district, providing access to a vibrant ecosystem of life science companies, research institutions, and talent. The facility includes state-of-the-art laboratory and office spaces.

Work Culture:

Characterized by a dynamic, innovative, and collaborative environment. Employees are typically mission-driven, focused on scientific rigor and a shared goal to develop transformative therapies for patients with serious diseases.

HQ Significance:

The Philadelphia headquarters is pivotal for Carisma's operations, as it is the primary site for the discovery, development, and advancement of its novel CAR-Macrophage platform technology and clinical programs.

Values Reflected in HQ: The headquarters' location and design reflect Carisma's commitment to innovation, cutting-edge science, collaboration, and its strategic position within a leading life sciences community.

Location:

While Carisma Therapeutics' primary operations and headquarters are based in the United States, its mission to develop novel cancer therapies has global implications. The company's research addresses diseases affecting patients worldwide, and its clinical trials may involve international sites. Future commercialization efforts for successful therapies would likely involve a global strategy to reach patients in need across different regions.

Street Address:

3675 Market Street, Suite 200

City:

Philadelphia

State/Province:

PA

Country:

USA

Carisma Therapeutics's Global Presence

Buying Intent Signals for Carisma Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Carisma Therapeutics

As of April 2025, Carisma Therapeutics' leadership includes:

Steven Kelly - President and Chief Executive Officer
Michael Klichinsky, PharmD, PhD - Chief Scientific Officer and Co-Founder
Richard Morris - Chief Financial Officer
Debora Barton, MD - Chief Medical Officer
Daniel Cushing, PhD - Chief Technical Officer
Tara Greig - Chief Strategy Officer

Investors of Carisma Therapeutics

Carisma Therapeutics has been backed by several prominent investors over the years, including:

AbbVie Ventures
HealthCap
Wellington Partners
SymBiosis II LP
Penn Medicine
TPG Biotech
Agent Capital
MSD Global Health Innovation Fund (Merck)
Moderna, Inc.
IP Group, Inc.

Executive New Hires/Exits in the Last 12 Months

Hire4
Exits1

In January 2024, Carisma Therapeutics announced significant leadership transitions to align with its strategic pipeline prioritization. This included the appointment of a new CEO, CFO, CTO, and Chief Strategy Officer, a transition for the co-founder to CSO, and the departure of the former CFO.

Departures

Christine O’Brien, CPA, Christine O’Brien, CPA, stepped down as Chief Financial Officer as part of a leadership transition.

New Appointments:

Steven Kelly, Steven Kelly, formerly President and CBO, appointed as President and CEO.
Richard Morris, Richard Morris appointed as Chief Financial Officer.
Michael Klichinsky, PharmD, PhD, Michael Klichinsky, Co-Founder, transitioned to the role of Chief Scientific Officer.
Daniel Cushing, PhD, Daniel Cushing, PhD, promoted to Chief Technical Officer.
Tara Greig, Tara Greig promoted to Chief Strategy Officer.

Technology (Tech Stack) used by Carisma Therapeutics

Discover the tools Carisma Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Carisma Therapeutics Email Formats and Examples

Carisma Therapeutics, Inc. commonly utilizes the email format [first_initial][last]@carismatx.com (e.g., jsmith@carismatx.com). This pattern is frequently observed for company communications.

[first_initial][last]@carismatx.com

Format

skelly@carismatx.com

Example

85%

Success rate

News and media

GlobeNewswireMay 14, 2024

Carisma Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Carisma Therapeutics announced its Q1 2024 financial results, providing updates on its clinical programs, including the CT-0508 HER2-targeted CAR-M and CT-0525 anti-PSMA CAR-M therapies. The company discussed its development strategy and financial position....more

GlobeNewswireMarch 7, 2024

Carisma Therapeutics’ CT-0508 Anti-HER2 CAR-M Receives Orphan Drug Designation from FDA for the Treatment of Gastric Cancer

The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Carisma Therapeutics' lead investigational candidate, CT-0508, an anti-HER2 CAR-Macrophage, for the treatment of gastric cancer. This designation aims to facilitate the development of therapies for rare conditions....more

GlobeNewswireJanuary 9, 2024

Carisma Therapeutics Announces Leadership Transition and Pipeline Prioritization to Focus on Advancement of Proprietary Engineered Macrophage Platform

Carisma Therapeutics announced significant leadership changes, with Steven Kelly becoming CEO and Michael Klichinsky transitioning to CSO. The company also outlined a pipeline prioritization to focus on its core engineered macrophage programs, CT-0508 and CT-0525....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Carisma Therapeutics, are just a search away.